Progesterone News and Research

RSS

TGen to present TNBC study at AACR 2012 annual meeting

Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.

2 Apr 2012

Transplanted ovaries can delay menopause and allow for a successful pregnancy

Researchers may have found a way to end menopause after proving that transplanted ovaries remain effective for at least seven years. Of the three women, one has had three children since her transplant, a second has had two and the third is expecting her third child. Medical experts believe the three could be the pioneers for a treatment that would allow women to delay motherhood.

26 Mar 2012

Testosterone receptor may be a potential target for triple negative breast cancer

Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).

26 Mar 2012

Testosterone may play a role in treatment of triple negative breast cancer

23 Mar 2012

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

23 Mar 2012

BHR Pharma enrolls first 400 patients for BHR-100 pivotal trial for TBI

As communities in the United States gather in support of Traumatic Brain Injury (TBI) Awareness Day, BHR Pharma, LLC's SyNAPSe- clinical trial reaches an important enrollment milestone.

22 Mar 2012

FDA clears Ventana PR (1E2) image analysis algorithm and digital read applications

Ventana Medical Systems, Inc., a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration for the VENTANA Companion Algorithm Progesterone Receptor (PR) (1E2) image analysis application used with the VENTANA iScan Coreo Au scanner running VIRTUOSO software.

14 Mar 2012

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson Pharmaceuticals, Inc. today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical intervention.

12 Mar 2012

Columbia Labs fourth quarter total net revenues decrease to $6.4M

Columbia Laboratories, Inc. today reported financial results for the three- and twelve-month periods ended December 31, 2011.

8 Mar 2012

WHO criticized for not efficiently communicating recommendations on HIV, contraception to African women, PlusNews reports

"HIV organizations, researchers and activists have criticized the WHO and UNAIDS for not clearly communicating guidelines on HIV and hormonal contraception to African women, who remain the most affected by the continent's high HIV prevalence rates," PlusNews reports.

3 Mar 2012

Watson introduces generic PROMETRIUM for endometrial hyperplasia

Watson Pharmaceuticals, Inc. today confirmed that Watson has launched an authorized generic version of PROMETRIUM (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories.

2 Mar 2012

Scientists discover that sperm do not function like olfactory cells

According to a 2003 study by German and American scientists, a component of the Lily of the Valley scent known as Bourgeonal alters the calcium balance of human sperm and attracts the sperm. The "Lily of the Valley phenomenon" - also the title of a book about smelling - was born as a result of this discovery that sperm act as swimming olfactory cells which follow a "scent trail" laid by the egg. However, a detailed explanation for the Lily of the Valley phenomenon remained illusive as neither Bourgeonal nor other scents could be identified in the female sex organ.

29 Feb 2012

FDA issues complete response letter for Watson's progesterone vaginal gel 8% NDA

Watson Pharmaceuticals, Inc. and Columbia Laboratories, Inc. today confirmed that, as expected, Watson has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.

27 Feb 2012

Seven scientists aim to make strides in predicting and preventing preterm birth

With the help of funding from the March of Dimes, researchers from five states and Canada are seeking answers to questions such as how cellular-level processes that control uterine muscles may affect preterm labor, the causes of preeclampsia, and how air pollution may affect pregnancy and preterm birth - all with the goal of preventing preterm birth so more babies will get a healthy start in life.

24 Feb 2012

New devices could hold key to predicting premature births

Scientists and doctors in Sheffield are developing two novel devices that they say could lead to the improved prediction of premature births.

16 Feb 2012

TFF3 protein plays a more sinister role in breast cancer metastasis

The trefoil factor 3 (TFF3) protein protects and maintains the integrity of the epithelial surface in the normal breast. New research has found that while TFF3 protein expression is higher in well-differentiated low grade tumors and therefore associated with features of a good prognosis, it has a more sinister role in breast cancer invasion and metastasis.

16 Feb 2012

Two novel devices can predict women at risk of premature birth

Scientists and doctors from the University of Sheffield are developing two novel devices that could lead to the improved prediction of premature births.

14 Feb 2012

Progesterone vaginal gel 8% NDA transferred to Watson

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced that Columbia has transferred the new drug application for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy (NDA 22-139) to Watson.

13 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Cyclin D1 oncogene may promote chromosomal instability

A team of researchers at Jefferson's Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression.

7 Feb 2012